Damora Therapeutics (DMRA) risk factors, FY2025 10-K

What changed since the prior 10-K

New

• NewRisks Related to Our Limited Operating History, Financial Position and Capital Requirements

  There is no guarantee that our acquisition of Pre-Acquisition Damora will increase stockholder value

  The acquisition of Pre-Acquisition Damora in November 2025 may fail to increase stockholder value and could cause management and business disruptions.

• NewRisks Related to Our Limited Operating History, Financial Position and Capital Requirements

  We are a preclinical stage biotechnology company with a limited operating history on which to assess our business; we have no products that have been administered to humans or approved for commercial sale, which may make it difficult to evaluate our current business and likelihood of success and viability

  We are a preclinical-stage biotechnology company with no products administered to humans or approved for commercial sale, making evaluation difficult.

• NewRisks Related to Our Limited Operating History, Financial Position and Capital Requirements

  We expect to continue to incur losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products approved for sale, have not generated any revenue from our product candidates and may never generate revenue or become profitable

  We have incurred operating losses since inception with no revenue and expect to continue incurring losses for the foreseeable future.

• NewRisks Related to Our Limited Operating History, Financial Position and Capital Requirements

  • continue to integrate Pre-Acquisition Damora into our operations

  Our expenses will increase due to integrating Pre-Acquisition Damora, potential FDA-mandated clinical trials, or intellectual property defense costs.

• NewRisks Related to Our Discovery, Development and Commercialization

  We face competition from entities that have developed or may develop product candidates for the diseases addressed by our product candidates

  Our product candidates will face intense competition from existing drugs like hydroxyurea, anagrelide, ruxolitinib, and interferon.

• NewRisks Related to Our Discovery, Development and Commercialization

  We are substantially dependent on the success of DMR-001, and our anticipated future clinical trials of such product candidate may not be successful

  Our success depends heavily on DMR-001, for which we plan to file an IND or CTA in mid-2026 and initiate a Phase 1 trial.

• NewRisks Related to Our Discovery, Development and Commercialization

  candidates, before we receive regulatory approval from the FDA and comparable foreign regulatory authorities, and we may never receive such regulatory approvals

  We do not control all factors necessary to receive regulatory approvals from the FDA and foreign authorities for our product candidates.

• NewRisks Related to Our Discovery, Development and Commercialization

  If we do not achieve our projected development objectives in the time frames we announce and expect, the commercialization of our product candidates may be delayed which may harm our reputation and prospects, increase our expenses and cause our stock price to decline

  Missing our projected development milestones for DMR-001, DMR-002, and DMR-003 could harm our reputation and cause our stock price to decline.

• NewRisks Related to Our Discovery, Development and Commercialization

  The target patient population for the treatment of MPNs is small and has not been definitively determined, and if estimates of the number of treatable patients is lower than expected, our potential revenues from sales of our product candidates, if approved, and our ability to achieve profitability would be compromised

  The target patient population for MPNs is small, with approximately 42,000 potential US patients with mutCALR proteins for DMR-001.

• NewRisks Related to Our Discovery, Development and Commercialization

  Our approach to the discovery and development of DMR-001, DMR-002 and DMR-003 is unproven, and we may not be successful in our efforts to build a pipeline of product candidates with commercial value

  Our approach using antibody engineering and half-life extension technologies is unproven with limited clinical data in autoimmune indications.

• NewRisks Related to Our Discovery, Development and Commercialization

  Currently, most ET patients are often treated with aspirin alone. However, the remaining ET patients carry a higher risk of clotting and bleeding and are generally treated with hydroxyurea, which is not approved for the treatment of ET in the United States, anagrelide or interferon

  Most ET patients are treated with aspirin alone, while remaining high-risk patients receive hydroxyurea, anagrelide, or interferon.

• NewRisks Related to Our Discovery, Development and Commercialization

  • continued enrollment of prospective patients by clinical trial sites

  Clinical trial enrollment and retention challenges could significantly delay development timelines and increase costs.

• NewRisks Related to Our Discovery, Development and Commercialization

  Preliminary, “topline” or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures

• NewRisks Related to Our Discovery, Development and Commercialization

  We may expend our resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success

• NewRisks Related to Our Discovery, Development and Commercialization

  Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue

• NewRisks Related to Our Discovery, Development and Commercialization

  We plan to conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations

• NewRisks Related to Our Reliance on Third Parties

  We rely on collaborations and licensing arrangements with third parties, including Paragon. If we are unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted

• NewRisks Related to Our Reliance on Third Parties

  Risks associated with the in-licensing or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of our product candidates

• NewRisks Related to Our Reliance on Third Parties

  and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the research program

• NewRisks Related to Our Business and Operations

  In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth

• NewRisks Related to Our Business and Operations

  We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy

• NewRisks Related to Our Business and Operations

  Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

• NewRisks Related to Our Business and Operations

  We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition

• NewRisks Related to Our Business and Operations

  We may acquire businesses, product candidates or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions

• NewRisks Related to Our Business and Operations

  We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments

• NewRisks Related to Our Intellectual Property

  Our intellectual property portfolio is at an early stage. Therefore, our ability to obtain and protect our patent rights, and protect other proprietary rights, is uncertain, exposing us to the possible loss of competitive advantage

• NewRisks Related to Our Intellectual Property

  If we are unable to obtain or maintain necessary rights to our programs through acquisitions and in-licenses, our business may be materially harmed

• NewRisks Related to Our Intellectual Property

  We may be subject to intellectual property lawsuits or may need to file lawsuits to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products

• NewRisks Related to Our Intellectual Property

  Our success will depend in part on our and our current and future licensors’ ability to obtain, maintain and enforce patent protection for our licensed intellectual property

• NewRisks Related to Our Intellectual Property

  We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties

• NewRisks Related to Our Intellectual Property

  We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products

• NewRisks Related to Our Intellectual Property

  We may become subject to claims challenging the inventorship or ownership of our patents, if issued, and other intellectual property

• NewRisks Related to Our Intellectual Property

  Our technology licensed from various third parties may be subject to retained rights

• NewRisks Related to Government Regulation

  We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates

• NewRisks Related to Government Regulation

  Our product candidates for which we intend to seek approval as biologics may face competition from biosimilars sooner than anticipated

• NewRisks Related to Government Regulation

  Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties

• NewRisks Related to Government Regulation

  Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business

• NewRisks Related to Government Regulation

  Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any

• NewRisks Related to Government Regulation

  We may become exposed to costly and damaging liability claims, when testing a product candidate in the clinical stage or at the commercial stage, and our product liability insurance may not cover all damages from such claims

• NewRisks Related to Government Regulation

  Litigation costs and the outcome of litigation could have a material adverse effect on our business

• NewRisks Related to Government Regulation

  Our business could be adversely affected by economic downturns, inflation, fluctuating interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition

• NewRisks Related to Government Regulation

  obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs

• NewRisks Related to the Ownership of Our Common Stock

  The market price of our common stock has been and is expected to continue to be volatile

• NewRisks Related to the Ownership of Our Common Stock

  • period-to-period fluctuations in our financial results

• NewRisks Related to the Ownership of Our Common Stock

  We are governed by Delaware law and our amended and restated certificate of incorporation, as amended (the “Certificate of Incorporation”) and amended and restated By-laws, as amended (the “By-laws”), provisions of which have anti-takeover implications

• NewRisks Related to the Ownership of Our Common Stock

  • require the affirmative vote of not less than 66 2/3% of the outstanding shares of capital stock entitled to vote on the matter to amend or repeal the By-laws if the board of directors does not recommend the same

• NewRisks Related to the Ownership of Our Common Stock

  Because our Certificate of Incorporation and By-laws limit the court in which you may bring an action against us, you may have difficulty obtaining a more favorable judicial forum or you may incur more expense enforcing any rights which you may claim as compared to another forum

• NewRisks Related to the Ownership of Our Common Stock

  We will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies

• NewRisks Related to the Ownership of Our Common Stock

  Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows

• NewRisks Related to the Ownership of Our Common Stock

  If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired

• NewRisks Related to the Ownership of Our Common Stock

  We do not anticipate that we will pay any cash dividends in the foreseeable future

• NewRisks Related to the Ownership of Our Common Stock

  Future sales of shares by existing stockholders could cause our stock price to decline

• NewRisks Related to the Ownership of Our Common Stock

  Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval

• NewRisks Related to the Ownership of Our Common Stock

  Conflicts of interest may arise between us and Paragon or us and Fairmount

• NewRisks Related to the Ownership of Our Common Stock

  Our ability to use net operating loss (“NOL”) carryforwards and other tax attributes may be limited, including as a result of our recent merger

• NewRisks Related to the Ownership of Our Common Stock

  The class structure of our capital stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions

• NewRisks Related to the Ownership of Our Common Stock

  correspondingly decreasing the voting power of the holders of common stock, which may limit your ability to influence corporate matters

Dropped

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  Following our strategic transaction with Bridge Medicines in October 2024, our focus is now on the development of GB3226 (previously referred to as BRM-1420) and GB1211. If we fail to execute successfully on this realigned strategic focus, our business and prospects will be adversely affected

  Strategic transaction with Bridge Medicines for GB3226 and GB1211 programs.

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in this Annual Report on Form 10-K

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  invest in or in-license other technologies or product candidates

  Independent accounting firm going concern explanatory paragraph.

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  SEC regulations limit the funds we can raise during 12 months under a shelf registration statement on Form S-3

  Historical net losses of $21.4 million in 2024 and $38.3 million in 2023.

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  The amount of our future losses is uncertain and our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline

  Requirement to invest in or in-license other technologies.

• DroppedRisks Related to Our Financial Position and Need for Additional Capital

  future accounting pronouncements or changes in our accounting policies

  SEC registration statement Form S-3 limits based on $7.3 million public float.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success

  Uncertainty of future losses and quarterly operating results fluctuation.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  GB3226 is currently in preclinical development and we may fail to show that the drug is generally safe and well tolerated and that it may provide clinical benefit for patients

  Impact of future accounting pronouncements and accounting policy changes.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials

  Limited operating history as former Galecto Biotech AB founded in 2011.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  the proprietary rights of others and their competing products and technologies that may prevent one of our product candidates from being commercialized

  Preclinical development risks for AML drug candidate GB3226.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our oncology or liver disease product candidates

  Lengthy and complex clinical development process uncertainties.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates

  FDA requirements for Phase 3 clinical trial diversity action plans.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected

  Oncology or liver disease product candidate development delays.

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  the risk that patients enrolled in clinical trials will drop out of the trials before completion

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  The design or execution of our ongoing and future clinical trials may not support marketing approval or commercialization

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  We intend to develop certain of our product candidates and potentially other product candidates in combination with other therapies, which exposes us to additional risks

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  We may not be able to obtain orphan drug exclusivity for our product candidates, which could limit the potential profitability of such product candidates

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  We may not be successful in our efforts to identify or discover additional product candidates in the future

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  decline in our share price

• DroppedRisks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

  We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  consent decrees or injunctions or the imposition of civil or criminal penalties

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  the prevalence and severity of any side effects

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  neither experimental nor investigational

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  The distribution of biotechnology and biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of biotechnology and biopharmaceutical products

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  legislative changes enacted by Congress or programmatic changes implemented at CMS by the Trump Administration, may impact the IRA drug price negotiation program in the future

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations

• DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

  Additional laws and regulations governing international operations, and the complexity associated with maintaining geographically diverse operations, could negatively impact or restrict our operations and ability to grow

• DroppedRisks Related to Our Intellectual Property

  Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection

• DroppedRisks Related to Our Intellectual Property

  We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates

• DroppedRisks Related to Our Intellectual Property

  If we breach any of the agreements under which we license from third parties the commercialization rights to our product candidates, we could lose license rights that are important to our business and our operations could be materially harmed

• DroppedRisks Related to Our Intellectual Property

  We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business

• DroppedRisks Related to Our Intellectual Property

  the priority of invention of patented technology

• DroppedRisks Related to Our Intellectual Property

  If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted, and our business and competitive position would be harmed

• DroppedRisks Related to Our Intellectual Property

  Third-party claims of intellectual property infringement may be costly and time consuming to defend, and could prevent or delay our product discovery, development and commercialization efforts

• DroppedRisks Related to Our Intellectual Property

  the need to redesign our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time

• DroppedRisks Related to Our Intellectual Property

  Third parties may assert that we are employing their proprietary technology without authorization

• DroppedRisks Related to Our Intellectual Property

  Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets

• DroppedRisks Related to Our Intellectual Property

  Others may claim an ownership interest in our intellectual property, which could expose us to litigation and have a significant adverse effect on our prospects

• DroppedRisks Related to Our Intellectual Property

  Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights

• DroppedRisks Related to Our Intellectual Property

  We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or challenging the patent rights of others, which could be expensive, time-consuming and unsuccessful

• DroppedRisks Related to Our Intellectual Property

  Any patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO

• DroppedRisks Related to Our Intellectual Property

  We have limited intellectual property rights outside of the United States and Europe and may not be able to protect and enforce our intellectual property rights throughout the world

• DroppedRisks Related to Our Intellectual Property

  If we do not obtain patent term extension and data exclusivity or similar non-U.S. legislation extending the term of protection covering any product candidates we may develop, our business may be materially harmed

• DroppedRisks Related to Our Intellectual Property

  If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

• DroppedRisks Related to Our Reliance on Third Parties

  If any of our relationships with these third-party CROs or other third parties terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms

• DroppedRisks Related to Our Reliance on Third Parties

  We depend on Rockefeller University to prosecute and maintain patents and patent applications that are material to our business. Any failure by a third party to effectively protect these intellectual property rights could adversely impact our business and operations

• DroppedRisks Related to Our Reliance on Third Parties

  We rely on third parties for materials, including tissue samples, required for our research and development activities, and if we are unable to reach agreements with these third parties, our research and development activities would be delayed

• DroppedRisks Related to Our Reliance on Third Parties

  in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products

• DroppedRisks Related to Our Reliance on Third Parties

  collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates

• DroppedRisks Related to Our Reliance on Third Parties

  Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected

• DroppedRisks Related to Managing Our Business and Operations

  We may encounter difficulties in managing our organization, which could adversely affect our operations

• DroppedRisks Related to Managing Our Business and Operations

  improving our operational, financial and management controls, reporting systems and procedures

• DroppedRisks Related to Managing Our Business and Operations

  If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive

• DroppedRisks Related to Managing Our Business and Operations

  and business, the disclosure of confidential or proprietary information, including personal data, damage our reputation and subject us to significant financial and legal exposure

• DroppedRisks Related to Managing Our Business and Operations

  We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from any such serious disaster

• DroppedRisks Related to Managing Our Business and Operations

  Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations

• DroppedRisks Related to Managing Our Business and Operations

  The increasing use of social media platforms presents new risks and challenges

• DroppedRisks Related to Managing Our Business and Operations

  We use and generate materials that may expose us to material liability

• DroppedRisks Related to Managing Our Business and Operations

  Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products

• DroppedRisks Related to Managing Our Business and Operations

  Changes in U.S. tax law could adversely affect our financial condition and results of operations

• DroppedRisks Related to Managing Our Business and Operations

  Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could expose us to greater than anticipated tax liabilities

• DroppedRisks Related to Managing Our Business and Operations

  Our corporate structure and intercompany arrangements are subject to the tax laws of various jurisdictions, and we could be obligated to pay additional taxes, which would harm our results of operations

• DroppedRisks Related to Managing Our Business and Operations

  Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation

• DroppedRisks Related to Managing Our Business and Operations

  We may become involved in securities class action litigation that could divert management’s attention and harm the company’s business, and insurance coverage may not be sufficient to cover all costs and damages

• DroppedRisks Related to Our Common Stock

  The price of our stock may be volatile, which could result in substantial losses for our stockholders

• DroppedRisks Related to Our Common Stock

  other events or factors, many of which are beyond our control

• DroppedRisks Related to Our Common Stock

  Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our common stock

• DroppedRisks Related to Our Common Stock

  We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock

• DroppedRisks Related to Our Common Stock

  We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors

• DroppedRisks Related to Our Common Stock

  Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates

• DroppedRisks Related to Our Common Stock

  We will continue to incur significant costs as a result of operating as a public company, and our management may be required to devote substantial time to new compliance initiatives

• DroppedRisks Related to Our Common Stock

  Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud

• DroppedRisks Related to Our Common Stock

  We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively

• DroppedRisks Related to Our Common Stock

  We can issue and have issued shares of preferred stock, which may adversely affect the rights of holders of our common stock

• DroppedRisks Related to Our Common Stock

  otherwise adversely affect the market price or our common stock

• DroppedRisks Related to Our Common Stock

  Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management

• DroppedRisks Related to Our Common Stock

  the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock

• DroppedRisks Related to Our Common Stock

  Our amended and restated by-laws, as amended, will designate certain courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to litigate disputes with us in a different judicial forum

• DroppedRisks Related to Our Common Stock

  Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders

Reworded

• 100% rewrittenRisks Related to Our Discovery, Development and Commercialization

  • the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial

  Updated to specify US and foreign regulatory requirements and IND acceptance processes for initiating clinical trials.

  Was: the FDA or other comparable foreign regulatory authorities may require us to submit additional nonclinical data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial

• 97% rewrittenRisks Related to Our Limited Operating History, Financial Position and Capital Requirements

  We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research programs or future commercialization efforts

  Added specific cash figure of $257.6 million as of December 31, 2025, lasting into Phase 3 development of DMR-001.

  Was: We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations

• 96% rewrittenRisks Related to Our Business and Operations

  Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

  Refined third-party misconduct scope to explicitly include CROs, CMOs, principal investigators, and commercial collaborators.

  Was: Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

• 96% rewrittenRisks Related to the Ownership of Our Common Stock

  If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, then our stock price and trading volume could decline

  Clarified that the trading market is influenced by equity research analyst reports and coverage lack.

  Was: If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline

• 95% rewrittenRisks Related to Our Limited Operating History, Financial Position and Capital Requirements

  • the costs of operating as a public company

  Updated going concern context with December 31, 2025 cash balance and Phase 3 runway threshold.

  Was: the costs of continuing to operate as a public company

• 94% rewrittenRisks Related to Government Regulation

  We may face difficulties from healthcare and regulatory legislative reform measures

  Generalised healthcare legislative reform risks to focus on potential future administrative actions and regulatory policies.

  Was: Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations

• 82% rewrittenRisks Related to Our Business and Operations

  If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

  Expanded hazardous materials disclosure to include flammable, chemical, and radioactive materials.

• 76% rewrittenRisks Related to Our Intellectual Property

  Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products

  Added specific reference to patent reform legislation such as the Leahy-Smith America Invents Act.

  Was: Changes in patent law in the United States and in other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products

• 70% rewrittenRisks Related to Our Business and Operations

  Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all

  Was: The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 10-K or that we may otherwise provide may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all

• 56% rewrittenRisks Related to Our Intellectual Property

  Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements

  Was: Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements

• 34% rewrittenRisks Related to Our Intellectual Property

  Patent terms may be inadequate to protect our competitive position of our product candidates for an adequate amount of time

  Was: Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time

All 68 risk factors

Headings as the filing states them, in filing order.

Other Damora Therapeutics 10-Ks

• FY2024 10-K risk factors

  99 risks

  Damora Therapeutics transitioned to oncology and liver diseases with GB3226 and GB1211 following the October 2024 Bridge Medicines transaction. The company faces a going concern warning, net losses of $21.4 million in 2024, and severe capital constraints with a public float of only $7.3 million.

  Filed Mar 19, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.